Menu
Recruiting NCT07732556

Midpoint Transverse Process to Pleura (MTP) Block vs Erector Spinae Plane (ESP) Block for Acute Herpes Zoster (HZ) Pain

No phase Interventional Midpoint Transverse Process to Pleura Block Erector Spinae Plane Block Acute Herpes Zoster Pain

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Midpoint transverse process to pleura block, Erector spinae plane block.
Who it may be relevant to
Registry conditions: Midpoint Transverse Process to Pleura Block, Erector Spinae Plane Block, Acute Herpes Zoster, Pain. Basic parameters: 21 years — 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Comparison Between Midpoint Transverse Process to Pleura (MTP) Block vs Erector Spinae Plane (ESP) Block for Acute Herpes Zoster (HZ) Pain

Overview

The aim of this study is to compare the analgesic efficacy and safety of ultrasound-guided midpoint transverse process block versus ultrasound-guided erector spinae plane block in patients suffering from thoracic herpes zoster pain.

Detailed description

Herpes zoster is caused by reactivation of latent varicella-zoster virus in dorsal root or cranial nerve ganglia and commonly presents with unilateral dermatomal rash associated with severe neuropathic pain.

The erector spinae plane block is an ultrasound-guided interfascial plane block in which local anesthetic is deposited deep to the erector spinae muscle adjacent to the transverse process, allowing multidermatomal spread and thoracic analgesia. Recent studies support its efficacy in herpes zoster pain management.

The midpoint transverse process to pleura block is a paravertebral-by-proxy technique where local anesthetic is injected midway between the posterior border of the transverse process and pleura. It may provide thoracic segmental analgesia with lower pleural puncture risk and easier sonoanatomy.

Interventions

  • Other Midpoint transverse process to pleura block
    Patients will receive ultrasound-guided midpoint transverse process to pleura block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone.
  • Other Erector spinae plane block
    Patients will receive ultrasound -guided erector spinae plane block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone.

Primary outcome measures

  • Incidence of post-herpatic neuralgia [Time frame: After 12 weeks of block]
Secondary outcome measures (9)
  • Blood pressure [Time frame: 24 hours postoperatively]
  • Heart rate [Time frame: 24 hours postoperatively]
  • Oxygen saturation [Time frame: 24 hours postoperatively]
  • Time to first rescue analgesia [Time frame: 24 hours postoperatively]
  • Total rescue analgesics consumption [Time frame: 24 hours postoperatively]
  • Degree of pain [Time frame: 12 weeks postoperatively]
  • Total anti-convulsant drugs [Time frame: 12 weeks postoperatively]
  • Assessment of sleep quality [Time frame: 12 weeks postoperatively]
  • Incidence of complications [Time frame: 24 hours postoperatively]

Eligibility criteria

Inclusion criteria

  • Age 21-60 years.
  • Both sexes.
  • American Society of Anesthesiologists (ASA) physical status I-II.
  • Acute thoracic herpes zoster within 30 days of rash onset.
  • Moderate to severe pain \[numeric rating scale (NRS)≥4\].

Exclusion criteria

  • Refusal to participate.
  • Coagulopathy or anticoagulant therapy.
  • Infection at puncture site.
  • Allergy to study drugs.
  • Severe psychiatric illness or inability to assess pain.
  • Previous thoracic surgery deformity.
  • Uncontrolled Diabetic patient.
  • Chronic diseases as renal, hepatic, malignancy.
  • Patients with chronic disease need analgesia.
  • Patients are coming for more than 3 months (after healing of rash).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Tanta University — Tanta

Identifiers

NCT: NCT07732556 · 36265MS150/6/26

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗